Replimune (REPL) Jumps As FDA Panel Backs Melanoma Drug Data

Replimune Group Inc. stocks have been trading up by 128.28 percent amid heightened optimism around its cancer therapy pipeline.

Live Update At 09:18:55 EDT: On Friday, July 31, 2026 Replimune Group Inc. stock [NASDAQ: REPL] is trending up by 128.28%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

REPL has traded like a biotech rollercoaster. Just days ago, Replimune Group Inc. sat near $11, then spiked toward the mid‑$10s and collapsed to $5.41 as traders digested the FDA advisory setup and headline risk. That’s more than a 50% drawdown in under two weeks on the daily chart, even with the recent pre‑market pop shown on the 5‑minute candles around $12–$13.

Under the hood, Replimune Group Inc. is still deep in the development phase. The latest quarterly numbers show revenue at effectively zero and a net loss of about $73.2M, or roughly -$0.76 per share. REPL burned about $56.2M in operating cash in the quarter, but ended with roughly $210.7M in cash and $268.9M when you include short‑term investments. That’s a decent runway.

Leverage sits at moderate levels for a biotech. Long‑term debt is about $107.5M, and liquidity ratios are strong, with a current ratio near 4.8. Return metrics for Replimune Group Inc. are sharply negative, which is standard for a clinical‑stage name without product revenue. For traders, this all says one thing: REPL is a pure catalyst and sentiment story, not a cash‑flow machine yet.

Why Traders Are Watching REPL After The FDA Vote

REPL just hit a major turning point. The FDA’s Cellular, Tissue, and Gene Therapies Advisory Committee voted 10–3 that data from Replimune Group Inc.’s IGNYTE trial of RP1 plus nivolumab in advanced melanoma are evaluable and clinically meaningful, even though the trial used a single‑arm design. In plain English, the panel said, “Yes, these results count.”

For a small cap like Replimune Group Inc., that kind of vote can reshape the entire trading landscape. Advisory committees don’t guarantee approval, but a wide 10–3 margin gives the market cover to believe RP1 is on a viable regulatory path. This is especially key because the combo with nivolumab is attacking a tough melanoma population, where unmet need is high and competition is serious.

The positive vote also supports the ongoing BLA resubmission for RP1 plus nivolumab, with a clear PDUFA date on 2026/08/02. That locks in a hard catalyst on the calendar. Traders who follow REPL now have a defined timeline and a supportive expert opinion backing the data package.

At the same time, Wedbush keeps a Neutral rating and a $9 target on Replimune Group Inc., despite expecting the panel to call the data clinically meaningful. Their stance highlights the remaining friction with the FDA over the single‑arm IGNYTE design and questions around how much each component contributes to efficacy. For REPL, that tension sets up a classic trading environment: big upside if the agency follows the panel, and real downside if the FDA pushes back again.

Conclusion

REPL is now a textbook biotech catalyst setup. Replimune Group Inc. just cleared a big psychological and regulatory hurdle with the 10–3 advisory committee vote, which effectively validates the RP1 plus nivolumab melanoma data as meaningful in the eyes of outside experts. That doesn’t erase the company’s steep quarterly losses or its heavy cash burn, but it does shift the conversation from “Will the FDA even consider this?” to “When and on what terms might they approve it?”

For active traders, that change matters more than any single earnings line item. REPL’s chart shows how violently sentiment can swing when headlines drive the tape — from double digits down to the mid‑single digits, then sharp pre‑market spikes as new information hits. Replimune Group Inc. is likely to stay a high‑volatility name as the BLA resubmission plays out and the 2026/08/02 PDUFA date gets closer.

Traders in this community know that stories like REPL reward preparation, not prediction. As Tim Sykes loves to hammer home, “Discipline and preparation beat hope and FOMO every time in trading.” As millionaire penny stock trader and teacher Tim Sykes says, “Preparation plus patience leads to big profits.”. For Replimune Group Inc., that means studying the regulatory path, watching liquidity and range, and being ready with a clear trading plan before the next RP1 headline hits. This is educational and research content only — use it to sharpen your process, not to chase blindly.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

• Penny Stocks Trading Guide
• Best Penny Stocks Under $1 to Buy Today
• Top 8 Penny Stocks to Watch on Robinhood

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

• AI Penny Stocks
• Robinhood Penny Stocks
• Top Biotech Stocks